Ractigen possesses a prominent IP position in RNAa and oligonucleotide delivery. At Ractigen’s core resides a powerful, high-throughput discovery engine allowing for the rapid identification of saRNAs. Our portfolio is built on composition of matter and methods of use for a growing library of therapeutic oligonucleotides. Medicinal chemistries and delivery platforms developed exclusively in-house further strength our IP estate and empower drug development.
Our Discovery Engine
It features a highly-refined bioinformatics algorithm integrating epigenetic datasets, design rules, and genome-wide on-target prediction tethered to in-house oligonucleotide manufacturing for saRNA synthesis followed by automated experimental validation of saRNA activity.
Target Gene Locus
Rapidly identify all saRNAs for any single target gene
Oligonucleotide manufacturing for in-house saRNA synthesis
In vitro Screening & Gene Expression
Automated rounds of dose-dependent gene expression
3-4 Weeks Start to Finish (All In-House)
Screen Hundreds of saRNA Candidates
Automated rounds of dose-dependent gene expression analytics and integrated de-risking safety assays allow for the screening of hundreds of saRNA candidates within 30-45 days.
Honing the Process
We are continually honing the process in pursuit of full-automation and continue to add to our ever-growing list of therapeutic genes expanding our IP estate and feeding our drug development pipeline.